Impact of interleukin-10 on phenotype and gene expression during early monocyte differentiation into dendritic cells

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 4791-4798

  Schwarz, Annika M ^a   Banning Eichenseer, Ursula ^b   Seidel, Kerstin ^a   Mauz KÖRHOLZ, Christine ^b   Körholz, Dieter ^b   Staege, Martin S ^b  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Dendritic cells; Differentiation; Gene expression; Interleukin 10

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 10;

ARTICLE; CELL DIFFERENTIATION; DENDRITIC CELL; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

DENDRITIC CELLS; DIFFERENTIATION; GENE EXPRESSION; INTERLEUKIN-10;

BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-10; INTERLEUKIN-4; MONOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE;

EID: 84891360659     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wang H, Nemoto-Sasaki Y, Kondo T, Akiyama M and Mukaida N: Potential involvement of monocyte chemoattractant protein (MCP)-1/CCL2 in IL-4-mediated tumor immunity through inducing dendritic cell migration into the draining lymph nodes. Int Immunopharmacol 3: 627-642, 2003.
2. Schuurhuis DH, Verdijk P, Schreibelt G, Aarntzen EH, Scharenborg N, de Boer A, van de Rakt MW, Kerkhoff M, Gerritsen MJ, Eijckeler F, Bonenkamp JJ, Blokx W, van Krieken JH, Boerman OC, Oyen WJ, Punt CJ, Figdor CG, Adema GJ and de Vries IJ: In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 69: 2927-2934, 2009.
3. Delirezh N, Moazzeni SM, Shokri F, Shokrgozar MA, Atri M and Kokhaei P: Autologous dendritic cells loaded with apoptotic tumor cells induce T-cell-mediated immune responses against breast cancer in vitro. Cell Immunol 257: 23-31, 2009.
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF and IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010.
5. Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI and Strieter RM: Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 145: 18-25, 1994.
6. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, Baccarani M and Lemoli RM: Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 100: 230-237, 2002.
7. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D and Carbone DP: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2: 1096-1103, 1996.
8. Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ, Pinedo HM, van den Eertwegh AJ, Scheper RJ and de Gruijl T: Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 168: 4333-4343, 2002.
9. Bekeredjian-Ding I, Schäfer M, Hartmann E, Pries R, Parcina M, Schneider P, Giese T, Endres S, Wollenberg B and Hartmann G: Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology 128: 439-450, 2009.
10. Gur-Wahnon D, Borovsky Z, Liebergall M and Rachmilewitz J: The induction of APC with a distinct tolerogenic phenotype via contact-dependent STAT3 activation. PloS One 4: e6846, 2009.
11. Coventry B and Heinzel S: CD1a in human cancers: A new role for an old molecule. Trends Immunol 25: 242-248, 2004.
12. Steinbrink K, Wolfl M, Jonuleit H, Knop J and Enk AH: Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159: 4772-4780, 1997.
13. Buelens C, Bartholomé EJ, Amraoui Z, Boutriaux M, Salmon I, Thielemans K, Willems F and Goldman M: Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell-stimulatory properties. Blood 99: 993-998, 2002.
14. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O and Moser M: Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 27: 1229-1235, 1997.
15. Thomssen H, Kahan M and Londei M: Differential effects of interleukin-10 on the expression of HLA class II and CD1 molecules induced by granulocyte/macrophage colony-stimulating factor/interleukin-4. Eur J Immunol 25: 2465-2470, 1995.
16. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP and Gabrilovich DI: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766, 2000.
17. Lissoni P, Vigore L, Ferranti R, Bukovec R, Meregalli S, Mandala M, Barni S, Tancini G, Fumagalli L and Giani L: Circulating dendritic cells in early and advanced cancer patients: Diminished percent in the metastatic disease. J Biol Regul Homeost Agents 13: 216-219, 1999.
18. Randolph GJ, Beaulieu S, Lebecque S, Steinman RM and Muller WA. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 282: 480-483, 1998.
19. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, Weissman IL, Cyster JG and Engleman EG: Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 3: 1135-1141, 2002.
20. Miltenyi S, Muller W, Weichel W and Radbruch A: High gradient magnetic cell separation with MACS. Cytometry 11: 231-238, 1990.
21. Ozdemir O, Ravindranath Y and Savasan S: Cell-mediated cytotoxicity evaluation using monoclonal antibody staining for target or effector cells with annexin V/propidium iodide co-labeling by fluorosphere-adjusted counts on three-color flow cytometry. Cytometry A 56: 53-60, 2003.
22. Larmonier N, Fraszczak J, Lakomy D, Bonnotte B and Katsanis E: Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother 59: 1-11, 2010.
23. Kim KD, Lim HY, Lee HG, Yoon DY, Choe YK, Choi I, Paik SG, Kim YS, Yang Y and Lim JS: Apolipoprotein A-I induces IL-10 and PGE-2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun 338: 1126-1136, 2005.
24. Beinhauer BG, McBride JM, Graf P, Pursch E, Bongers M, Rogy M, Korthauer U, de Vries JE, Aversa G and Jung T: Interleukin-10 regulates cell surface and soluble LIR-2 (CD85d) expression on dendritic cells resulting in T-cell hyporesponsiveness in vitro . Eur J Immunol 34: 74-80, 2004.
25. de Gruijl TD, Sombroek CC, Lougheed SM, Oosterhoff D, Buter J, van den Eertwegh AJ, Scheper RJ and Pinedo HM: A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. J Immunol 176: 7232-7242, 2006.
26. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L and Mantovani A: IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 28: 359-369, 1998.
27. Williams LM, Ricchetti G, Sarma U, Smallie T, and Foxwell BM: Interleukin-10 suppression of myeloid cell activation - a continuing puzzle. Immunology 113: 281-292, 2004.
28. Corinti S, Albanesi C, la Sala A, Pastore S and Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 166: 4312-4318, 2001.
29. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000.
30. Stockwin LH, McGonagle D, Martin IG and Blair GE: Dendritic cells: Immunological sentinels with a central role in health and disease. Immunol Cell Biol 78: 91-102, 2000.
31. Fortsch D, Rollinghoff M and Stenger S: IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis. J Immunol 165: 978-987, 2000.
32. Foti M, Granucci F, Aggujaro D, Liboi E, Luini W, Minardi S, Mantovani A, Sozzani S and Ricciardi-Castagnoli P: Upon dendritic cell (DC) activation chemokines and chemokine receptor expression are rapidly regulated for recruitment and maintenance of DC at the inflammatory site. Int Immunol 11: 979-986, 1999.
33. + T-cell response. J Leukoc Biol 78: 898-908, 2005.
34. Sun T, Cao H, Xu L, Zhu B, Gu Q and Xu X: Insulin-like growth factor binding protein-related protein 1 mediates VEGF-induced proliferation, migration and tube formation of retinal endothelial cells. Curr Eye Res 36: 341-349, 2011.
35. Li H, Cheung W, Choo HH, Chan JH, Lai PS and Fred Wong WS: IL-10 synergistically enhances GM-CSF-induced CCR1 expression in myelomonocytic cells. Biochem Biophys Res Commun 304: 417-424, 2003.
36. D'Amico G, Frascaroli G, Bianchi G, Transidico P, Doni A, Vecchi A, Sozzani S, Allavena P and Mantovani A: Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat Immunol 1: 387-391, 2000.
37. Carl VS, Gautam JK, Comeau LD and Smith MF, Jr.: Role of endogenous IL-10 in LPS-induced STAT3 activation and IL-1 receptor antagonist gene expression. J Leukoc Biol 76: 735-742, 2004.
38. Arend WP, Smith MF, Jr., Janson RW and Joslin FG: IL-1 receptor antagonist and IL-1β production in human monocytes are regulated differently. J Immunol 147: 1530-1536, 1991.
39. Sun Z, Zhang R, Wang H, Jiang P, Zhang J, Zhang M, Gu L, Yang X, Zhang M and Ji X: Serum IL-10 from systemic lupus erythematosus patients suppresses the differentiation and function of monocyte-derived dendritic cells. J Biomed Res 26: 456-466, 2012.
40. Lech-Maranda E, Mlynarski W, Grzybowska-Izydorczyk O, Borowiec M, Pastorczak A, Cebula-Obrzut B, Klimkiewicz-Wojciechowska G, Wcislo M, Majewski M, Kotkowska A, Robak T and Warzocha K: Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes Chromosomes Cancer 52: 287-296, 2013.
41. Schoof N, Franklin J, Fürst R, Zander T, von Bonin F, Peyrade F, Trümper L, Diehl V, Engert A, Kube D and Re D: Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma. Oncologist 18: 80-89, 2013.
42. de la Cruz-Merino L, Lejeune M, Nogales Fernández E, Henao Carrasco F, Grueso López A, Illescas Vacas A, Pulla MP, Callau C and Álvaro T: Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: A whole new world with therapeutic implications. Clin Dev Immunol 2012: 756353, 2012.
43. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M and Cabanillas F: Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 10: 433- 440, 1999.
44. Liu WH, Liu JJ, Wu J, Zhang LL, Liu F, Yin L, Zhang MM and Yu B: Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One 8: e55487, 2013.
45. Pérez-Simon JA, López-Villar O, Andreu EJ, Rifón J, Muntion S, Campelo MD, Sánchez-Guijo FM, Martinez C, Valcarcel D and Cañizo CD: Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: Results of a phase I/II clinical trial. Haematologica 96: 1072-1076, 2011.
46. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R and Kurtzberg J: Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 17: 534-541, 2011.
47. Galipeau J: The mesenchymal stromal cells dilemma - Does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus -host disease represent a death knell or a bump in the road? Cytotherapy 15: 2-8, 2013.